ProteoNic Biosciences announced a partnership with Ginkgo Bioworks. This strategic alliance will grant Ginkgo Bioworks’ customers access to ProteoNic’s vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications. This also marks ProteoNic’s joining the Ginkgo Technology Network, a groundbreaking ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Cathie Wood’s ARK Investment bought 5.8M shares of Ginkgo Bioworks today
- Ginkgo Bioworks price target lowered to $3 from $7 at TD Cowen
- Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
- Ginkgo Bioworks sees FY24 revenue $215M-$235M, consensus $279.55M
- Ginkgo Bioworks reports Q4 EPS (11c), consensus (10c)
